Elixiron's Phase 2 Study Yields Positive Results for Enrupatinib in Alzheimer's Treatment
Elixiron's Promising Phase 2 Results on Enrupatinib
Elixiron Immunotherapeutics, a pioneering biopharmaceutical company headquartered in Cambridge, Massachusetts, has announced promising interim results from their ongoing Phase 2 clinical trial concerning enrupatinib (also known as EI-1071). This phase of the study has shown potential in addressing neuroinflammation in Alzheimer's disease, garnering attention due to the significant implications for future treatments.
Study Overview
The interim analysis is part of a proof-of-concept study supported by the Alzheimer's Association's
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.